Daratumumab is an anti-CD38 monoclonal antibody that directs Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cellular Phagocytosis (ADCP) as well as ADCC of CD38+ MM cells mediated by NK cells. This evidence concerns the gene CD38 and Miyoshi myopathy.